期刊文献+

脑卒中的预后与干预

The prognosis of stroke intervention
原文传递
导出
摘要 目的:探讨综合干预对脑卒中患者生活质量的影响研究。方法:选择128例脑卒中病人随机分为观察组与对照组。对照组常规治疗与护理,观察组除常规治疗护理外,给予康复训练程序、日常生活能力评分(ADL)训练的综合干预措施,观察综合干预对生活质量的影响。结果:观察组和对照组在神经功能缺损评分方面比较差异有显著性(P〈O.05),两组病人ADL比较无统计学意义(P〉0.05)。结论:综合干预能促进脑功能重组,显著改善肢体运动功能及日常生活活动,减轻残疾程度,提高生活质量。 Objective:To evaluate the comprehensive intervention on quality of life of patients with stroke research. Methods: 128 patients were randomly divided into two groups of stroke patients and the control group. The control group conventional treatment and care, in addition to conventional treatment and nursing observation group, the given rehabilitation training program, activities of daily living score (ADL) training,comprehensive intervention, observe the comprehensive intervention on quality of life in stroke patients. Results:The observation group and control group in terms of neurological function was significant difference (P〈0.05), wo groups showed no statistically significant ADL (P〉 0.05). Conclusion:The comprehensive intervention can promote reorganization of brain function, significantly improved motor function and activities of daily living, reduce disability and improve quality of life.
作者 李炳棋
出处 《按摩与康复医学》 2011年第15期40-41,共2页 Chinese Manipulation and Rehabilitation Medicine
关键词 脑卒中 康复训练 预后 影响 Stroke Rehabilitation training Prognosis
  • 相关文献

参考文献2

二级参考文献14

  • 1Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med, 2008, 359: 1317-1329.
  • 2Del Zoppo GJ, Saver JL, Jauch EC, et al; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke, 2009, 40: 2945-2948.
  • 3The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333: 1581-1587.
  • 4Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA, 1995, 274: 1017-1025.
  • 5Hacke W, Kaste M, Fieschi C, et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS Ⅱ). Lancet, 1998, 352: 1245-1251.
  • 6Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 1999, 282: 2019-2026.
  • 7Hickenbottom SL, Barsan WG. Acute ischemic stroke therapy. Neurol Clin, 2000, 18: 379-397.
  • 8Demchuk AM, Morgenstem LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke, 1999, 30: 34-39.
  • 9Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT Ⅱ trial. Neurology, 2001,57: 1603-1610.
  • 10Fiebach JB, Schellinger PD. MR mismatch is useful for patient selection for thrombolysis: yes. Stroke, 2009, 40: 2906-2907.

共引文献15771

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部